ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Allergan (AGN)
09/27/201613:00:00Orange County Business Council Study Showcases Economic Impact...
09/27/201608:05:00Allergan to Present New Data at the American Urogynecologic Society...
09/26/201611:00:00Pfizer Won't Pursue a Split of Established and New Medical Lines
09/23/201616:30:00Allergan Announces FDA Approval of NATRELLE INSPIRA® Cohesive...
09/22/201609:00:00Biotechnology Companies Reaching New Milestones
09/22/201608:00:00Allergan and Adamas Announce U.S. Availability of New Dosage...
09/20/201616:15:00Allergan Acquires Akarna Therapeutics Adding to its Strong Development...
09/20/201609:50:00Allergan Agrees to Buy Tobira Therapeutics in $1.7 Billion Deal
09/20/201609:04:10Current Report Filing (8-k)
09/20/201608:00:00Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D...
09/14/201609:40:00Allergan to Buy Vitae Pharmaceuticals for $639 Million
09/14/201609:21:56Current Report Filing (8-k)
09/14/201608:00:00Allergan and Medicines360 Announce Launch of New LILETTA® (levonorgestrel-releasing...
09/14/201608:00:00Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development...
09/13/201608:00:00Allergan Showcases Commitment to Eye Care Innovation with New...
09/07/201608:00:00Medicines360 and Allergan announce publication of levonorgestrel...
09/06/201608:00:00Allergan Acquires Gene Therapy Company RetroSense Therapeutics...
09/01/201607:30:00Allergan to Present at Morgan Stanley Global Healthcare Conference
08/31/201608:00:00Allergan and Adamas Announce Settlement with Amneal Related to...
08/22/201608:50:00Pfizer Adds Key Cancer Drug in $14 Billion Biotech Deal

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations